Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BM-ECs and PRPE for Critical Limb Ischemia
NCT02993809Phase 1Unknown
- Sponsor
- South China Institute for Stem Cell Biology and Regenerative Medicine
- Start
- Mar 2018
- Primary completion
- Dec 2019
01
Overview
Phase 1 trial in critical limb ischemia (CLI), sponsored by South China Institute for Stem Cell Biology and Regenerative Medicine. Primary endpoint: Survival without major amputation at 6 months. Status: unknown.
02
Conditions
critical limb ischemia (CLI)
Beyond the preview
Go deeper on NCT02993809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02993809.